Kid-size doses of Pfizer’s COVID-19 vaccine appear safe and nearly 91 per cent effective at preventing symptomatic infections in 5 to 11-year-olds, according to study details released Friday as the US considers opening vaccinations to that age group.The shots could begin in early November — with the first children in line fully protected by Christmas — if regulators give the go-ahead.Details of Pfizer's study were posted online. The Food and Drug Administration was expected to post its independent review of the company's safety and effectiveness data later in the day.
Load More
Load More